Serial anti-VEGF injections could increase IOP

Article

Administering serial antivascular endothelial growth factor (VEGF) injections could lead to increased intraocular pressure (IOP) and may require glaucoma therapy

Administering serial antivascular endothelial growth factor (VEGF) injections could lead to increased intraocular pressure (IOP) and may require glaucoma therapy, according to the Journal of Glaucoma.

Dr Joseph J. Tseng, Vitreous Retina Macula Consultants of New York, New York, USA, led a investigation consisting of 25 eyes of 23 patients with neovascular age-related macular degeneration (AMD). All patients has increased IOP whilst receiving interval doses of ranibizumab or bevacizumab. All patients had no previous IOP elevations and tolerated multiple anti-VEGF injections.

Patients received a mean of 20 anti-VEGF injections and the mean IOP was 29.8 mmHg, compared to a mean baseline of 16.9 mmHg. The highest IOP recorded was 35.8 mmHg.

Of the patients included in the study, 23 of 25 cases underwent IOP management and two cases switched from regular anti-VEGF doses to an optical coherence tomography-guided variable regimen.

The elevation in IOP can occur even if the patient previously tolerated multiple anti-VEGF injections. The results warrant further investigation into the link between anti-VEGF therapy and IOP.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.